Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women

• Published in: The journal of clinical endocrinology and metabolism Vol. 89; no. 5; pp. 2290 - 2300
• Main Authors: Bowers, Cyril Y., Granda, Ramona, Mohan, Subburaman, Kuipers, Jonathan, Baylink, David, Veldhuis, Johannes D.
• Format: Journal Article
• Language: English
• Published: Bethesda, MD Oxford University Press 01.05.2004; Copyright by The Endocrine Society; Endocrine Society
• Subjects: Aged; Aging; Agonists; Biological and medical sciences; Cohort Studies; Drug Administration Schedule; Endocrinopathies; Feeding. Feeding behavior; Female; Fundamental and applied biological sciences. Psychology; Geriatrics; Growth hormone-releasing hormone; Human Growth Hormone - secretion; Humans; Infusion Pumps; Injections, Intravenous; Injections, Subcutaneous; Insulin-Like Growth Factor Binding Protein 3 - blood; Insulin-Like Growth Factor Binding Protein 5 - blood; Insulin-like growth factor I; Insulin-Like Growth Factor I - metabolism; Insulin-like growth factor-binding protein 3; Insulin-like growth factor-binding protein 5; Insulin-like growth factors; Male; Medical sciences; Middle Aged; Older people; Oligopeptides - administration & dosage; Osmolar Concentration; Peptides; Protein folding; Pulsatile Flow; Reference Values; Secretion; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Vertebrates: endocrinology; Women; Human; Nutrition; Peptides; Continuous; Subcutaneous; Secretion; Somatotropin hormone; Metabolic diseases; Concentration; Insulin like growth factor 1; Binding protein; Adenohypophyseal hormone; Pulsatile; Perfusion; Female; Endocrinology
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2003-031799

We test the interlinked hypotheses that in healthy older adults: 1) iv injection of GH-releasing peptide-2 (GHRP-2) and GHRH synergizes more in aging women than men; 2) sc infusion of both GHRP-2 (1 μg/kg·h = 1) and GHRH (1, 3, or 10) for 24 h augments GH secretion more than either agonist alone; and 3) continuous sc delivery of GHRP-2 (1) for 30 d stimulates daily GH secretion and IGF-I, IGF-binding protein-3 (IGFBP-3), and IGFBP-5. Acute two-peptide synergy was 3-fold greater in young (n = 16) than older volunteers (n = 17; P < 0.025) and was 2.3-fold higher in elderly women than men (P < 0.025). The 24-h infusion of GHRP-2 (1) combined with GHRH (3 or 10) in men and with GHRH (10) in women drove GH secretion more than GHRH alone (P ≤ 0.024). In the entire cohort (n = 11), GHRP-2/GHRH (1/10) stimulated GH secretion more than either GHRP-2 (1; P = 0.021) or GHRH (10; P = 0.012). The 30-d delivery of GHRP-2 (1; n = 17 subjects): 1) stimulated pulsatile, rhythmic, and entropic GH secretion by more than 3-fold on d 1 and more than 1.8-fold on d 14 and 30 (each P < 0.001 vs. saline); 2) elevated IGF-I to a stable plateau on d 1, 14, and 30 (P < 0.025 vs. baseline); and 3) increased IGFBP-3 (P < 0.01) and IGFBP-5 (P < 0.025) on d 14 and/or 30. Safety screening tests remained normal. In summary, in healthy elderly women and men: 1) acute synergy of GHRP-2 and GHRH is greater in the female; 2) 24-h combined GHRP-2 and GHRH drive is more effective than either agonist alone; and 3) 30-d stimulation with GHRP-2 sustains a physiologically activated somatotropic axis. We conclude that age, gender, stimulus duration, and secretagogue combination determine acute, intermediate, and extended responses of the somatotropic axis in the older adult.